Apologies to Paul Simon, but there must be 50 ways to leave your employer.
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
In short, CEOs can't be afraid to walk away from their most profitable line if another approach may lead to improved long-term outcomes.
I'm not suggesting that colleges become vocational schools. But don't you think they should also help young people prepare for the life they're going to be living?
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
You can see it everywhere: on TV and in newspapers and ads. The decades of struggle against cancer are paying off.
Until now, your superiors have promoted you. Now it's your responsibility to show why you belong.
Why would any CEO tolerate a corporate culture that holds people back?
When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Drugmakers battle for slice of Humira's billions
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- Five things for pharma marketers to know: Thursday, April 27, 2017
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.